Alzheimer’s Disease Clinical Trial Reaches Halfway Mark for Enrollment

May 2, 2016

PROVIDENCE, R.I. – Rhode Island Hospital is recruiting local participants for an international clinical trial to test an investigational drug intervention that may reduce the risk and development of Alzheimer’s disease. The Anti-Amyloid Treatment in Asymptomatic Alzheimer’s Disease (A4) clinical trial is for individuals ages 65 to 85 who may be at risk for memory loss due to Alzheimer’s disease. The trial is funded in part by the National Institutes of Health.

“This multicenter trial has reached its halfway mark for A4 randomization goals in the U.S. and Canada, and is quickly approaching 50 percent of total international enrollment of 1,150 participants, including Australian enrollment,” said Brian Ott, M.D., director of the Alzheimer’s Disease and Memory Disorders Center at Rhode Island Hospital. “A record number of 426 participants are in the screening process worldwide, but we still have a ways to go to reach the finish line. The study would like to complete enrollment within the next year and close screening by the end of 2016.”

The A4 study is testing an anti-amyloid investigational drug in older individuals who have evidence of elevated amyloid accumulation in their brain but who do not yet show symptoms of Alzheimer’s disease. The goal is to slow possible Alzheimer’s-related damage in the brain and to delay symptoms of memory loss. The drug, which binds to amyloid proteins, is expected to slow decline in memory and thinking as measured by cognitive tests, if treatment is started before there is evidence of Alzheimer’s-related symptoms and brain injury.

Each participant is required to undergo a positron emission tomography (PET) scan to measure amyloid in the brain. Participants with normal thinking and memory abilities, an elevated amyloid level, and who pass screening evaluations of their general health will be randomly assigned to receive either the investigative antibody drug or a placebo, given by an intravenous infusion every four weeks. Participants will be monitored for the duration of the trial.

Alzheimer’s disease affects more than 20,000 people in Rhode Island, 5 million people in the U.S., and 35 million people worldwide. It is the sixth-leading cause of death in the U.S. and the only cause of death among the top 10 in the U.S. that cannot be prevented, cured or even slowed.

For more information on the study, or to find out if you qualify, please contact Kerstin Calia at 401-444-9861 or kcalia@lifespan.org.

About Rhode Island Hospital

Founded in 1863, Rhode Island Hospital in Providence, R.I., is a private, not-for-profit hospital and is the principal teaching hospital of Alpert Medical School of Brown University. A major trauma center for southeastern New England, the hospital is dedicated to being on the cutting edge of medicine and research. Last year, Rhode Island Hospital received more than $50 million in external research funding. It is also home to Hasbro Children’s Hospital, the state’s only facility dedicated to pediatric care. For more information, visit www.rhodeislandhospital.org.

Media Contact

Christina Spaight O'Reilly

Rhode Island Hospital
401-444-6421
christina.oreilly@lifespan.org